Where Ph.D.s Morph Into M.B.A.s

As a postdoc at the University of California, San Francisco, Christopher Trepel studied the cellular mechanisms of memory in cats and rats until he ran into a serious obstacle: His allergies to the animals had become intolerable. He was also allergic to mice, guinea pigs, and rabbits. "I was fast running out of animals," Trepel recalls. "I kept moving up the food chain. I was going to have to use humans, and that's prohibited." He also had a qualm about academic science: A professor trains 40 pe

Written byDouglas Steinberg
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

One day, Trepel, contemplating his love for science, his allergies, and his other options, attended a presentation at UCSF by the management-consulting firm McKinsey & Co. The talk piqued his interest. So he brushed up on economics and interviewing techniques and eventually got a job. In the past decade, many talented scientists like Trepel have left labs for consulting firms, where some draw six-figure incomes. This research-to-riches migration intensified in 1998, 1999, and 2000. That's when M.B.A. holders headed for dot-com startups and consulting firms increasingly turned to academia for able applicants, says Betsy Kovacs, president of the Association of Management Consulting Firms in New York.

Global consulting-firm revenues swelled as the U.S. economy expanded, averaging 19 percent annual growth from 1995 to 1999, according to Kennedy Information Research Group (KIRG) in Fitzwilliam, N.H. Revenues topped $114 billion in 2000 and are expected to reach $130 billion this year. With ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies